Opportunity Information: Apply for PAR 14 106
Apply for PAR 14 106
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Feb 25, 2014 and posted on Feb 25, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Independent school districts For profit organizations other than small businesses Special district governments State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01)" (Funding Opportunity Number PAR-14-106) is a discretionary National Institutes of Health (NIH) research grant designed to expand what is known about synthetic psychoactive drugs and to support practical strategies that reduce the harms associated with their use. In plain terms, the program is aimed at funding rigorous research that helps the public health and clinical communities better understand how these drugs are being used, how they work in the body and brain, what short- and long-term health consequences they cause, and what can be done to prevent use and improve treatment. A notable emphasis of the description is on both acute care needs, such as how to treat patients who present in emergency departments, and longer-range approaches to treatment and recovery after the immediate crisis has passed.
This opportunity uses the NIH R01 mechanism, meaning it is intended for mature, hypothesis-driven research projects with well-developed aims and methods, typically conducted by established research teams or investigators prepared to carry out a substantial multi-year study. The overall topic area falls under federal research programming for drug abuse and addiction, identified by CFDA number 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement, which means applicants are not required to contribute a set portion of project costs from non-federal sources as a condition of receiving an award.
From a scientific and public health perspective, the announcement’s scope centers on synthetic psychoactive substances, which commonly refers to human-made compounds that mimic or alter the effects of traditional drugs but may have different potency, toxicity, and risk profiles. The FOA’s language highlights several priority directions: documenting and characterizing patterns of use (who is using, how, and in what contexts), clarifying mechanisms of action (how these drugs interact with receptors, neural circuits, and physiological systems), mapping health effects (including toxicology, overdose risk, psychiatric and medical complications, and longer-term outcomes), and developing prevention and intervention strategies. Importantly, the description points to two clinical horizons that often need different solutions: immediate stabilization and management in emergency settings, and longer-term treatment approaches that address dependence, relapse prevention, mental health sequelae, and recovery supports.
Eligibility is broad and intentionally inclusive, reflecting NIH’s common practice of allowing a wide range of organizational types to apply when the scientific need is urgent and cross-cutting. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including 501(c)(3) entities and nonprofits without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and multiple levels of government such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities or Indian housing authorities. Tribal eligibility is also explicitly included, covering federally recognized Native American tribal governments and tribal organizations. In addition, the FOA lists a wide set of other eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
A key feature of this particular announcement is that it permits participation by non-U.S. entities. Non-domestic (non-U.S.) organizations and foreign institutions are eligible to apply, and non-domestic components of U.S. organizations may also participate. Foreign components, as defined in the NIH Grants Policy Statement, are allowed, which signals that NIH was open to international collaboration and research settings when they strengthen the science, for example by enabling access to different patterns of synthetic drug emergence, distinct healthcare system responses, or specialized analytic capabilities.
Administratively, the opportunity was posted and created on February 25, 2014, with an original closing date of May 7, 2017, and the same date listed as the current closing date. It was archived on June 7, 2017, meaning it is no longer active for new submissions under that specific announcement as written, but it remains a useful reference point for the kind of research NIH sought to stimulate during that period. The sponsoring agency is the National Institutes of Health, and the public-facing announcement is linked through the NIH grants guide. For technical access issues, the listed point of contact is the NIH Office of Extramural Research (OER) webmaster email addresses provided in the source text.
Overall, the FOA can be read as NIH’s effort to accelerate high-quality research that connects basic and translational science to real-world prevention and treatment needs in response to rapidly evolving synthetic drug markets. It encourages work that not only explains what these substances do and why they are harmful, but also produces actionable knowledge for clinicians, emergency departments, public health systems, and community prevention efforts aimed at reducing morbidity and mortality and improving long-term outcomes.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01)" and the Funding Opportunity Number is PAR-14-106.
Which agency sponsors this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What kind of grant mechanism is used?
This opportunity uses the NIH R01 mechanism, which is generally intended for mature, hypothesis-driven research projects with well-developed specific aims and methods, typically supporting substantial multi-year studies.
What is the main purpose of the funding opportunity?
The purpose is to expand scientific and public health knowledge about synthetic psychoactive drugs and to support practical strategies that reduce the harms associated with their use. The emphasis is on rigorous research that improves understanding of use patterns, biological mechanisms, health consequences, and prevention/treatment approaches.
What topic area or program classification does this fall under?
The opportunity is associated with federal drug abuse and addiction research programming under CFDA 93.279, Drug Abuse and Addiction Research Programs.
What types of substances are in scope for this opportunity?
The scope centers on synthetic psychoactive substances, described as human-made compounds that mimic or alter the effects of traditional drugs and may differ in potency, toxicity, and risk profiles.
What kinds of research questions or aims does the FOA emphasize?
The description highlights multiple priority directions, including: documenting and characterizing patterns of use; clarifying mechanisms of action (for example, interactions with receptors, neural circuits, and physiological systems); mapping health effects and outcomes; and developing prevention and intervention strategies to reduce harm.
Does the opportunity emphasize clinical response as well as basic science?
Yes. The FOA stresses both acute care needs (such as management of patients presenting to emergency departments) and longer-range approaches to treatment and recovery after the immediate crisis has passed.
What does the FOA mean by two different clinical horizons?
It points to two areas that often require different solutions: (1) immediate stabilization and management in emergency settings, and (2) longer-term treatment approaches addressing dependence, relapse prevention, mental health sequelae, and recovery supports.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement, meaning applicants are not required to contribute a set portion of project costs from non-federal sources as a condition of award.
Who is eligible to apply?
Eligibility is broad and includes many organization types, such as public and private institutions of higher education; nonprofit organizations (including 501(c)(3) and nonprofits without 501(c)(3) status); for-profit organizations (including small businesses and other for-profits); and multiple levels of government (state, county, city or township, special district, independent school district, and public housing authorities or Indian housing authorities).
Are Tribal governments and Tribal organizations eligible?
Yes. The FOA explicitly includes federally recognized Native American tribal governments and tribal organizations as eligible applicants.
Are minority-serving institutions and similar organizations listed as eligible?
Yes. The FOA lists several categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations allowed to apply?
Yes. Faith-based or community-based organizations are included among the eligible applicant categories listed in the description.
Can for-profit organizations apply?
Yes. For-profit organizations, including small businesses and other for-profit entities, are listed as eligible applicants.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. A notable feature of this FOA is that non-domestic (non-U.S.) organizations and foreign institutions are eligible to apply.
Can a U.S. organization include a non-U.S. component in its project?
Yes. The FOA indicates that non-domestic components of U.S. organizations may participate, and foreign components (as defined in the NIH Grants Policy Statement) are allowed.
Why would NIH allow foreign components or foreign applicants for this topic?
The FOA language signals openness to international collaboration and settings when they strengthen the science, such as enabling access to different patterns of synthetic drug emergence, different healthcare system responses, or specialized analytic capabilities.
When was this opportunity posted and when did it close?
It was posted/created on February 25, 2014. The original closing date was May 7, 2017, and the same date is listed as the current closing date in the provided information.
Is this funding opportunity still active?
No. The opportunity was archived on June 7, 2017, which means it is no longer active for new submissions under that specific announcement as written.
Where was the public announcement made available?
The public-facing announcement is linked through the NIH grants guide (as described in the opportunity summary).
Who is the technical contact for access issues related to the announcement?
For technical access issues, the listed point of contact is the NIH Office of Extramural Research (OER) webmaster email addresses referenced in the source text.
What overall impact is NIH trying to achieve with this FOA?
The FOA can be read as an NIH effort to accelerate high-quality research that connects basic and translational science to real-world prevention and treatment needs in response to rapidly evolving synthetic drug markets, producing actionable knowledge for clinicians, emergency departments, public health systems, and community prevention efforts.
Browse more opportunities from the same category: Education Health
Next opportunity: Logistics, Travel, and Support for Law Enforcement and Rule of Law Programs in the Caribbean
Previous opportunity: Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 106
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 106) also looked into and applied for these:
| Funding Opportunity |
|---|
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 14 152 Funding Number: PAR 14 152 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 14 160 Funding Number: PAR 14 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03) Apply for PA 14 164 Funding Number: PA 14 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21) Apply for PA 14 162 Funding Number: PA 14 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01) Apply for PA 14 163 Funding Number: PA 14 163 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) Apply for RFA DA 15 006 Funding Number: RFA DA 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R01) Apply for PAR 14 166 Funding Number: PAR 14 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Physical Sciences Oncology Centers (U54) Apply for PAR 14 169 Funding Number: PAR 14 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) Apply for RFA DA 15 007 Funding Number: RFA DA 15 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21) Apply for PA 14 176 Funding Number: PA 14 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 106", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.